Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Somatostatin Receptor Positron Emission Tomography: Beyond Gastroenteropancreatic Neuroendocrine Tumors

Somatostatin Receptor Positron Emission Tomography: Beyond Gastroenteropancreatic Neuroendocrine... Curr Radiol Rep (2019) 7:15 (0123456789().,-volV)(0123456789().,-volV) https://doi.org/10.1007/s40134-019-0322-z NUCLEAR MEDICINE & PET/CT IMAGING (R FLAVELL, SECTION EDITOR) Somatostatin Receptor Positron Emission Tomography: Beyond Gastroenteropancreatic Neuroendocrine Tumors 1 2 Gagandeep Choudhary Samuel Galgano Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract with PRRT using peptides labeled with yttrium-90 ( Y) or Purpose of Review Similar to various gastroenteropancre- lutetium-177 ( Lu) beta emitters will also be discussed. atic (GEP) neuroendocrine tumors (NETs), somatostatin Summary SSTR-PET imaging with [ Ga]DOTA-peptides receptors (SSTRs) are overexpressed in a wide array of has utility in malignant and benign conditions other than malignant and benign conditions. Using somatostatin GEP-NETs. Combining SSTR-PET with other anatomic positron emission tomography (PET) analogs and functional imaging modalities has demonstrated ([ Ga]DOTA-peptides) this overexpression of SSTRs can superior diagnostic accuracy. The presence of SSTRs in be exploited for clinical management in terms of diagnosis, these conditions opens up new possibilities in the man- therapy, and for peptide receptor radionuclide therapy agement of these conditions in terms of imaging and (PRRT). therapeutics. Recent Findings Recent reports suggest that [ Ga]DOTA- peptide PET tracers have an emerging role in the man- Keywords Somatostatin receptor  Medullary thyroid agement of wide array http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Radiology Reports Springer Journals

Somatostatin Receptor Positron Emission Tomography: Beyond Gastroenteropancreatic Neuroendocrine Tumors

Download PDF
10 pages

Loading next page...
 
/lp/springer-journals/somatostatin-receptor-positron-emission-tomography-beyond-kZlh0GMkDl

References (56)

Publisher
Springer Journals
Copyright
Copyright © 2019 by Springer Science+Business Media, LLC, part of Springer Nature
Subject
Medicine & Public Health; Imaging / Radiology
eISSN
2167-4825
DOI
10.1007/s40134-019-0322-z
Publisher site
See Article on Publisher Site

Abstract

Curr Radiol Rep (2019) 7:15 (0123456789().,-volV)(0123456789().,-volV) https://doi.org/10.1007/s40134-019-0322-z NUCLEAR MEDICINE & PET/CT IMAGING (R FLAVELL, SECTION EDITOR) Somatostatin Receptor Positron Emission Tomography: Beyond Gastroenteropancreatic Neuroendocrine Tumors 1 2 Gagandeep Choudhary Samuel Galgano Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract with PRRT using peptides labeled with yttrium-90 ( Y) or Purpose of Review Similar to various gastroenteropancre- lutetium-177 ( Lu) beta emitters will also be discussed. atic (GEP) neuroendocrine tumors (NETs), somatostatin Summary SSTR-PET imaging with [ Ga]DOTA-peptides receptors (SSTRs) are overexpressed in a wide array of has utility in malignant and benign conditions other than malignant and benign conditions. Using somatostatin GEP-NETs. Combining SSTR-PET with other anatomic positron emission tomography (PET) analogs and functional imaging modalities has demonstrated ([ Ga]DOTA-peptides) this overexpression of SSTRs can superior diagnostic accuracy. The presence of SSTRs in be exploited for clinical management in terms of diagnosis, these conditions opens up new possibilities in the man- therapy, and for peptide receptor radionuclide therapy agement of these conditions in terms of imaging and (PRRT). therapeutics. Recent Findings Recent reports suggest that [ Ga]DOTA- peptide PET tracers have an emerging role in the man- Keywords Somatostatin receptor  Medullary thyroid agement of wide array

Journal

Current Radiology Reports – Springer Journals

Published: Mar 25, 2019

There are no references for this article.